[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
December 17, 2014

Optimal Antiviral Prophylaxis Against Hepatitis B Reactivation in Patients Receiving Rituximab-Based Chemotherapy for Lymphoma

Author Affiliations
  • 1Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston
  • 2Harvard Medical School, Boston, Massachusetts
  • 3Liver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston
JAMA. 2014;312(23):2505-2507. doi:10.1001/jama.2014.16095

Approximately 350 million people worldwide (5% of the world’s population) are infected with the hepatitis B virus (HBV), characterized by presence of the HBV surface antigen.1 Carriers of HBV will harbor undetectable or very low HBV DNA levels with normal alanine aminotransferase (ALT) levels, whereas those with active HBV will harbor higher HBV DNA levels, often with elevated ALT levels. Others will have cleared the virus, characterized by absence of hepatitis B surface antigen or detectable levels of HBV DNA, and by the presence of the HBV core antibody, with or without hepatitis B surface antibodies.

First Page Preview View Large
First page PDF preview
First page PDF preview
×